Amarna Therapeutics has announced today that it has entered into a collaboration with scientists from the Progreso y Salud Foundation (FPS) at Cabimer in Seville, to jointly examine the efficacy of Amarna’s SVec™ gene delivery vector for the development of effective immunotherapies for diabetes mellitus type 1 (DM1) and multiple sclerosis (MS).

A case report published today in The Lancet Respiratory Medicine outlines the first compassionate use of recombinant soluble human ACE2 (APN01) to treat a female 45-year-old patient who was diagnosed with severe COVID-19.

ENPICOM, an innovative bioinformatics software engineering company specialized in decoding the immune system, announced that the Princess Margaret Cancer Centre of the University Health Network (UHN) has purchased a subscription to ENPICOM’s data analysis platform.

OXGENE™, a biotechnology company designing and developing scalable gene therapy technologies, has today announced the launch of its scalable, plasmid-free manufacturing system for AAV. OXGENE’s new TESSA™ technology addresses industry-wide challenges associated with robust and reproducible AAV manufacture at scale. These include high cost of goods, and low packaging efficiency. TESSA aims to deliver a paradigm shift in scalable AAV manufacture.

ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property announced it has signed an agreement with Applied StemCell, Inc., a leading provider of stem cell, animal model, antibody discovery services and reagents to commercialize CRISPR gene editing.

PCR Biosystems has today launched RiboShield™ RNase Inhibitor. Already an important component of several PCR Biosystems kits, this robust and reliable RNase inhibitor is, for the first time, available as a standalone product.

Illumina announced today that the Australian public health laboratories will aim to sequence the virus genomes of all positive COVID-19 tests in Australia and track COVID-19 using genomics across the country, rather than state by state, under a ground-breaking initiative spearheaded by Australia’s public health laboratory organisations and leading industry partners.

Promega has launched its benchtop capillary electrophoresis (CE) instrument, the Spectrum Compact CE System, developed in collaboration with Hitachi High-Tech.

Daicel Arbor has announced an advance in the latest myBaits kit reagent chemistry and associated protocol referred to as myBaits Version 5.

Thermo Fisher Scientific has announced a new portfolio of hematology-oncology assays for the Ion Torrent Genexus System designed to enable a future in which turnaround times for next-generation sequencing results can be reduced to less than 24 hours.